News >

Biomarker Development Critical to Continued Progress in NSCLC

Danielle Bucco
Published: Friday, Mar 23, 2018

Jeffrey Melson Clarke, MD

Jeffrey Melson Clarke, MD
Biomarkers have revolutionized the treatment of patients with non–small cell lung cancer (NSCLC), becoming an essential component of treatment and enabling the implementation of precision medicine.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Clarke, an assistant professor of medicine in the Department of Medicine at Duke University School of Medicine, discussed the latest developments with biomarkers in NSCLC.

OncLive: Please provide an overview of your presentation on biomarker testing for patients with NSCLC.

Clarke: The use of biomarkers for NSCLC is incredibly important. We have seen biomarkers evolve over the past several years for routine clinical use to directly care for patients with NSCLC. Typically, biomarkers for NSCLC can be broken down into genotyping and determine selection of patients for immunotherapy. There are different ways to perform genotyping for patients with lung cancer, either using tissue-based genotyping methods or plasma-based methods. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x